Abercrombie & Fitch: Can Hollister Shine Again This Quarter?
Abercrombie & Fitch (ANF) reports quarter earnings Wednesday. Analysts expect revenue of $1.16 billion and eps of $1.1. The estimate represents over 25% revenue...
Urban Outfitters: All About Guidance
Urban Outfitters (URBN) reports quarterly earnings after-hours. Analysts expect revenue of $1.08 billion and eps of $0.63. The $1.08 billion estimate likely reflects a...
Will Weak Guidance Sink Target?
Target (TGT) reports quarterly earnings Tuesday. Analysts expect revenue of $22.53 billion and eps of $1.38. I expect this to be an important earnings...
CSX Sticks With Harrison’s Plan To Cut Jobs, Reduce Trains
CSX (CSX) recently affirmed it would stick with former CEO Hunter Harrison's plan to cut jobs and rail cars, and slash capital spending:
U.S. railroad...
Weatherford’s Debt Load Is Untenable
I have been a Weatherford (WFT) bear for a few years now. In November 2016 I predicted the company was insolvent by about $4...
Mylan’s Growth Is Dead
Mylan reported Q4 revenue of $3.2 billion and eps of $1.43. The company missed on revenue by $60 million, but beat on earnings. The...
Valeant: Who Can Stomach Double-Digit Revenue Declines?
Valeant (VRX) reported Q4 earnings earlier this week. The company delivered revenue of $2.163 billion and adjusted net income of $347 million. Valeant missed...
Allergan: Botox Biosimilar From Mylan And Revance Sounds Ominous
Mylan (MYL) and Revance Therapeutics (RVNC) announced a global collaboration and license agreement to develop and commercialize a biosimilar for Allergan's (AGN) Botox:
Mylan N.V....
Mallinckrodt: Acthar, Deteriorating Credit Metrics Are Concerning
Mallinckrodt (MNK) reported FQ4 revenue of $792 million and eps of $2.01. It beat on revenue by $18 million and beat on earnings by...
Judge Holds ‘Pharma Bro’ Shkreli Responsible For $10 Million In Losses
"Pharma Bro" Martin Shkreli sparked a public outcry for hiking the price of a life-saving drug by 5,000%. Prior to that he was ousted...
